Loading...

Nippon Shinyaku

OTCPK:NPPN.Y
Snowflake Description

Flawless balance sheet with acceptable track record.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
NPPN.Y
OTCPK
¥567B
Market Cap
Add to portfolio
  1. Home
    2. ›
  2. US
    3. ›
  3. Pharmaceuticals & Biotech
Last updated 2019/06/20 01:17
Company description

Nippon Shinyaku Co., Ltd. manufactures and sells pharmaceuticals and foodstuffs in Japan, Europe, and internationally. The last earnings update was 38 days ago. More info.

Find similar companies

Add to Portfolio Compare Print
NPPN.Y Share Price and Events
7 Day Returns
0%
OTCPK:NPPN.Y
1%
US Pharmaceuticals
1.2%
US Market
1 Year Returns
12.3%
OTCPK:NPPN.Y
8%
US Pharmaceuticals
2.3%
US Market
NPPN.Y Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Nippon Shinyaku (NPPN.Y) 0% 0.1% 10.9% 12.3% - -
US Pharmaceuticals 1% 1.5% -2.2% 8% 10.2% 16%
US Market 1.2% 2% 2% 2.3% 37.9% 39.8%
1 Year Return vs Industry and Market
  • NPPN.Y outperformed the Pharmaceuticals industry which returned 8% over the past year.
  • NPPN.Y outperformed the Market in United States of America which returned 2.3% over the past year.
Price Volatility
NPPN.Y
Industry
5yr Volatility vs Market

NPPN.Y Value

 Is Nippon Shinyaku undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Nippon Shinyaku to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Nippon Shinyaku.

OTCPK:NPPN.Y Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 9 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 7.5%
Perpetual Growth Rate 10-Year US Government Bond Rate 2.7%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for OTCPK:NPPN.Y
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year US Govt Bond Rate 2.7%
Equity Risk Premium S&P Global 6%
Pharmaceuticals Unlevered Beta Simply Wall St/ S&P Global 0.64
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.641 (1 + (1- 30.86%) (0%)) 		0.76
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)		 0.8
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 2.73% + (0.8 * 5.96%) 		7.5%

Discounted Cash Flow Calculation for OTCPK:NPPN.Y using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Nippon Shinyaku is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

OTCPK:NPPN.Y DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (JPY, Millions) Source Present Value
Discounted (@ 7.5%)
2019 14,417.14 Analyst x7 13,411.55
2020 20,081.17 Analyst x6 17,377.54
2021 23,417.17 Analyst x6 18,850.95
2022 28,061.67 Analyst x6 21,014.15
2023 35,727.00 Analyst x2 24,888.27
2024 40,208.00 Analyst x2 26,056.15
2025 43,852.23 Est @ 9.06% 26,435.59
2026 46,993.54 Est @ 7.16% 26,353.30
2027 49,734.85 Est @ 5.83% 25,945.22
2028 52,173.04 Est @ 4.9% 25,318.75
Present value of next 10 years cash flows ¥225,651.46
OTCPK:NPPN.Y DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= ¥52,173.04 × (1 + 2.73%) ÷ (7.5% – 2.73%) 		¥1,124,105.74
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= ¥1,124,105.74 ÷ (1 + 7.5%)10 		¥545,510.76
OTCPK:NPPN.Y Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= ¥225,651.46 + ¥545,510.76 		¥771,162.22
Equity Value per Share
(JPY)		 = Total value / Shares Outstanding
= ¥771,162.22 / 67.35 		¥11449.35
OTCPK:NPPN.Y Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in OTCPK:NPPN.Y represents 0.00216x of TSE:4516
(This could be a different class, a depositary receipt, a different currency, or all of these things.) 		0.00216x
Value per Share
(Listing Adjusted, USD)		 = Value per Share (JPY) x Listing Adjustment Factor
= ¥ 11,449.35 x 0.00216 		$24.75
Value per share (USD) From above. $24.75
Current discount Discount to share price of $18.20
= -1 x ($18.20 - $24.75) / $24.75 		26.5%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Nippon Shinyaku is available for.
Intrinsic value
26%
Share price is $18.2 vs Future cash flow value of $24.75
Current Discount Checks
For Nippon Shinyaku to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Nippon Shinyaku's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Nippon Shinyaku's share price is below the future cash flow value, but not at a substantial discount (< 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Nippon Shinyaku's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Nippon Shinyaku's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
OTCPK:NPPN.Y PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in JPY ¥242.03
TSE:4516 Share Price ** TSE (2019-05-28) in JPY ¥8420
United States of America Pharmaceuticals Industry PE Ratio Median Figure of 29 Publicly-Listed Pharmaceuticals Companies 17.17x
United States of America Market PE Ratio Median Figure of 3,092 Publicly-Listed Companies 17.87x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Nippon Shinyaku.

OTCPK:NPPN.Y PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= TSE:4516 Share Price ÷ EPS (both in JPY)

= 8420 ÷ 242.03

 34.79x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Nippon Shinyaku is overvalued based on earnings compared to the US Pharmaceuticals industry average.
  • Nippon Shinyaku is overvalued based on earnings compared to the United States of America market.
Price based on expected Growth
Does Nippon Shinyaku's expected growth come at a high price?
Raw Data
OTCPK:NPPN.Y PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 34.79x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 9 Analysts		 16.4%per year
United States of America Pharmaceuticals Industry PEG Ratio Median Figure of 21 Publicly-Listed Pharmaceuticals Companies 1.61x
United States of America Market PEG Ratio Median Figure of 2,128 Publicly-Listed Companies 1.53x

*Line of best fit is calculated by linear regression .

OTCPK:NPPN.Y PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 34.79x ÷ 16.4%

 2.12x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Nippon Shinyaku is poor value based on expected growth next year.
Price based on value of assets
What value do investors place on Nippon Shinyaku's assets?
Raw Data
OTCPK:NPPN.Y PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in JPY ¥2,003.33
TSE:4516 Share Price * TSE (2019-05-28) in JPY ¥8420
United States of America Pharmaceuticals Industry PB Ratio Median Figure of 183 Publicly-Listed Pharmaceuticals Companies 3.24x
United States of America Market PB Ratio Median Figure of 5,246 Publicly-Listed Companies 1.8x
OTCPK:NPPN.Y PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= TSE:4516 Share Price ÷ Book Value per Share (both in JPY)

= 8420 ÷ 2,003.33

 4.2x

* Primary Listing of Nippon Shinyaku.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Nippon Shinyaku is overvalued based on assets compared to the US Pharmaceuticals industry average.
X
Value checks
We assess Nippon Shinyaku's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
    5. Nippon Shinyaku has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

NPPN.Y Future Performance

 How is Nippon Shinyaku expected to perform in the next 1 to 3 years based on estimates from 9 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
16.4%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Nippon Shinyaku expected to grow at an attractive rate?
  • Nippon Shinyaku's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Growth vs Market Checks
  • Nippon Shinyaku's earnings growth is expected to exceed the United States of America market average.
  • Nippon Shinyaku's revenue growth is positive but not above the United States of America market average.
Annual Growth Rates Comparison
Raw Data
OTCPK:NPPN.Y Future Growth Rates Data Sources
Data Point Source Value (per year)
OTCPK:NPPN.Y Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 9 Analysts 16.4%
OTCPK:NPPN.Y Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 9 Analysts 6.3%
United States of America Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 14.8%
United States of America Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 5.4%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 13.9%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.4%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
OTCPK:NPPN.Y Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 9 Analyst Estimates (S&P Global) See Below
All numbers in JPY Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
OTCPK:NPPN.Y Future Estimates Data
Date (Data in JPY Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-03-31 153,998 39,132 36,745 4
2023-03-31 148,714 35,611 34,036 5
2022-03-31 142,619 30,345 29,915 8
2021-03-31 132,808 25,584 25,072 9
2020-03-31 120,082 22,331 19,227 8
OTCPK:NPPN.Y Past Financials Data
Date (Data in JPY Millions) Revenue Cash Flow Net Income *
2019-03-31 114,716 15,310 16,302
2018-12-31 110,764 13,991
2018-09-30 105,279 13,565 11,992
2018-06-30 105,034 12,958
2018-03-31 101,448 6,719 12,953
2017-12-31 100,224 10,134
2017-09-30 103,943 9,977 14,264
2017-06-30 99,250 12,630
2017-03-31 98,781 18,916 11,749
2016-12-31 97,006 14,598
2016-09-30 89,300 15,904 9,300
2016-06-30 88,692 8,809

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Nippon Shinyaku's earnings are expected to grow by 16.4% yearly, however this is not considered high growth (20% yearly).
  • Nippon Shinyaku's revenue is expected to grow by 6.3% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
OTCPK:NPPN.Y Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 9 Analyst Estimates (S&P Global) See Below

All data from Nippon Shinyaku Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

OTCPK:NPPN.Y Future Estimates Data
Date (Data in JPY Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-03-31 545.55 794.31 416.90 4.00
2023-03-31 505.34 663.66 391.70 5.00
2022-03-31 444.15 522.61 365.40 8.00
2021-03-31 376.98 437.64 286.10 10.00
2020-03-31 286.37 310.78 264.27 9.00
OTCPK:NPPN.Y Past Financials Data
Date (Data in JPY Millions) EPS *
2019-03-31 242.03
2018-12-31 207.72
2018-09-30 178.04
2018-06-30 192.39
2018-03-31 192.31
2017-12-31 150.45
2017-09-30 211.76
2017-06-30 187.50
2017-03-31 174.42
2016-12-31 216.71
2016-09-30 138.06
2016-06-30 130.76

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Nippon Shinyaku is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
X
Future performance checks
We assess Nippon Shinyaku's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Nippon Shinyaku has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

NPPN.Y Past Performance

  How has Nippon Shinyaku performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Nippon Shinyaku's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Nippon Shinyaku has delivered over 20% year on year earnings growth in the past 5 years.
  • Nippon Shinyaku's 1-year earnings growth exceeds its 5-year average (25.9% vs 22.6%)
  • Nippon Shinyaku's earnings growth has not exceeded the US Pharmaceuticals industry average in the past year (25.9% vs 40.4%).
Earnings and Revenue History
Nippon Shinyaku's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Nippon Shinyaku Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

OTCPK:NPPN.Y Past Revenue, Cash Flow and Net Income Data
Date (Data in JPY Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 114,716.00 16,302.00 26,069.00 16,701.00
2018-12-31 110,764.00 13,991.00 25,610.00 15,897.00
2018-09-30 105,279.00 11,992.00 25,124.00 14,815.00
2018-06-30 105,034.00 12,958.00 24,558.00 14,084.00
2018-03-31 101,448.00 12,953.00 23,760.00 13,221.00
2017-12-31 100,224.00 10,134.00 24,319.00 16,104.00
2017-09-30 103,943.00 14,264.00 23,854.00 16,121.00
2017-06-30 99,250.00 12,630.00 23,567.00 14,584.00
2017-03-31 98,781.00 11,749.00 23,367.00 14,903.00
2016-12-31 97,006.00 14,598.00 22,087.00 10,439.00
2016-09-30 89,300.00 9,300.00 21,644.00 10,066.00
2016-06-30 88,692.00 8,809.00 21,574.00 9,669.00
2016-03-31 84,209.00 6,340.00 21,560.00 9,739.00
2015-12-31 84,764.00 6,559.00 21,382.00 9,394.00
2015-09-30 82,934.00 5,965.00 21,279.00 9,450.00
2015-06-30 81,312.00 5,799.00 21,145.00 9,353.00
2015-03-31 79,991.00 5,882.00 20,917.00 8,968.00
2014-12-31 79,394.00 6,191.00 20,720.00 9,152.00
2014-09-30 77,394.00 5,045.00 20,537.00 9,241.00
2014-06-30 76,840.00 5,269.00 20,179.00 9,413.00
2014-03-31 76,517.00 5,750.00 19,546.00 9,530.00
2013-12-31 74,240.00 4,989.00 19,395.00 9,740.00
2013-09-30 72,391.00 4,699.00 19,150.00 9,463.00
2013-06-30 71,003.00 4,538.00 18,928.00 9,379.00
2013-03-31 69,941.00 4,647.00 18,892.00 9,049.00
2012-12-31 68,395.00 4,191.00 18,893.00 8,970.00
2012-09-30 68,274.00 3,796.00 18,868.00 9,173.00
2012-06-30 67,853.00 3,686.00 18,855.00 9,278.00

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Nippon Shinyaku has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • Nippon Shinyaku used its assets less efficiently than the US Pharmaceuticals industry average last year based on Return on Assets.
  • Nippon Shinyaku has significantly improved its use of capital last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess Nippon Shinyaku's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Nippon Shinyaku has a total score of 3/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

NPPN.Y Health

 How is Nippon Shinyaku's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Nippon Shinyaku's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Nippon Shinyaku is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Nippon Shinyaku's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Nippon Shinyaku's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Nippon Shinyaku has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Nippon Shinyaku Company Filings, last reported 2 months ago.

OTCPK:NPPN.Y Past Debt and Equity Data
Date (Data in JPY Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 135,189.00 0.00 42,138.00
2018-12-31 132,212.00 0.00 33,458.00
2018-09-30 130,896.00 0.00 34,517.00
2018-06-30 127,334.00 0.00 31,291.00
2018-03-31 125,687.00 0.00 32,886.00
2017-12-31 125,059.00 0.00 26,047.00
2017-09-30 120,695.00 0.00 32,120.00
2017-06-30 117,387.00 0.00 34,506.00
2017-03-31 114,315.00 0.00 39,438.00
2016-12-31 115,190.00 0.00 25,514.00
2016-09-30 105,961.00 0.00 30,211.00
2016-06-30 104,643.00 0.00 29,742.00
2016-03-31 102,761.00 0.00 28,061.00
2015-12-31 106,320.00 0.00 17,992.00
2015-09-30 101,761.00 0.00 19,948.00
2015-06-30 102,173.00 0.00 21,405.00
2015-03-31 101,206.00 0.00 22,640.00
2014-12-31 97,364.00 0.00 19,011.00
2014-09-30 94,540.00 0.00 20,343.00
2014-06-30 93,442.00 0.00 19,228.00
2014-03-31 93,185.00 0.00 21,496.00
2013-12-31 93,131.00 0.00 16,979.00
2013-09-30 91,272.00 0.00 23,559.00
2013-06-30 90,011.00 0.00 19,844.00
2013-03-31 89,528.00 0.00 20,286.00
2012-12-31 86,654.00 0.00 19,331.00
2012-09-30 85,368.00 0.00 22,832.00
2012-06-30 84,702.00 0.00 21,284.00
  • Nippon Shinyaku has no debt.
  • Nippon Shinyaku has not taken on any debt in the past 5 years.
  • Nippon Shinyaku has no debt, it does not need to be covered by operating cash flow.
  • Nippon Shinyaku has no debt, therefore coverage of interest payments is not a concern.
Show me more healthy companies in the Pharmaceuticals industry
X
Financial health checks
We assess Nippon Shinyaku's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
    7. Nippon Shinyaku has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

NPPN.Y Dividends

 What is Nippon Shinyaku's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0.69%
Current annual income from Nippon Shinyaku dividends. Estimated to be 1.37% next year.
If you bought $2,000 of Nippon Shinyaku shares you are expected to receive $14 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Nippon Shinyaku's pays a lower dividend yield than the bottom 25% of dividend payers in United States of America (1.44%).
  • Nippon Shinyaku's dividend is below the markets top 25% of dividend payers in United States of America (3.69%).
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
OTCPK:NPPN.Y Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 9 Analyst Estimates (S&P Global) See Below
United States of America Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 10 Stocks 2.7%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 2011 Stocks 2.4%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.4%
United States of America Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

OTCPK:NPPN.Y Future Dividends Estimate Data
Date (Data in ¥) Dividend per Share (annual) Avg. No. Analysts
2024-03-31 162.75 4.00
2023-03-31 148.75 4.00
2022-03-31 123.71 7.00
2021-03-31 107.34 10.00
2020-03-31 85.93 10.00
OTCPK:NPPN.Y Past Annualized Dividends Data
Date (Data in ¥) Dividend per share (annual) Avg. Yield (%)
2019-02-08 58.000 0.769
2019-02-06 58.000 0.815
2018-11-08 58.000 0.819
2018-11-06 58.000 0.854
2018-06-29 58.000 0.884
2018-05-09 58.000 0.782
2018-02-06 52.000 0.752
2017-11-06 52.000 0.652
2017-08-14 50.000 0.652
2017-08-09 50.000 0.708
2017-06-30 48.000 0.678
2017-05-11 50.000 0.739
2017-02-10 36.000 0.610
2017-02-08 38.000 0.661
2016-11-10 36.000 0.642
2016-11-08 38.000 0.742
2016-06-30 35.000 0.666
2016-05-12 35.000 0.636
2016-02-10 28.000 0.650
2016-02-08 28.000 0.682
2015-11-10 28.000 0.604
2015-11-06 28.000 0.553
2015-08-07 28.000 0.642
2015-06-29 28.000 0.700
2015-05-11 28.000 0.726
2015-02-10 26.000 0.628
2015-02-06 26.000 0.666
2014-11-12 26.000 0.700
2014-11-10 26.000 0.824
2014-08-08 25.000 0.798
2014-06-30 24.000 0.816
2014-05-09 25.000 1.160
2014-02-10 22.000 1.168
2014-02-06 24.000 1.254
2013-11-07 22.000 1.140
2013-08-07 23.000 1.375
2013-06-28 22.000 1.269
2013-05-13 23.000 1.441
2013-02-06 22.000 1.659
2012-11-06 22.000 2.146
2012-08-06 21.000 2.203
2012-06-29 21.000 2.199
2012-05-10 21.000 2.339
2012-02-06 19.000 1.922
2011-11-08 19.000 2.094
2011-08-05 19.000 2.004
2011-06-30 19.000 1.789
2011-05-12 19.000 1.900
2011-02-08 19.000 1.809
2010-06-30 19.000 1.713
2010-05-14 19.000 1.947
2010-02-10 20.000 1.943
2010-02-09 20.000 1.977
2009-11-11 18.000 1.711
2009-11-10 20.000 1.670
2009-06-30 18.000 1.490

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Nippon Shinyaku is not paying a notable dividend for United States of America, therefore no need to check if the payments are stable.
  • Nippon Shinyaku is not paying a notable dividend for United States of America, therefore no need to check if the payments are increasing.
Current Payout to shareholders
What portion of Nippon Shinyaku's earnings are paid to the shareholders as a dividend.
  • No need to calculate the sustainability of Nippon Shinyaku's dividends as it is not paying a notable one for United States of America.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Nippon Shinyaku's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Nippon Shinyaku afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
    7. Nippon Shinyaku has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

NPPN.Y Management

 What is the CEO of Nippon Shinyaku's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Shigenobu Maekawa
AGE 65
TENURE AS CEO 12 years
CEO Bio

Mr. Shigenobu Maekawa has been President of Nippon Shinyaku Co., Ltd., since June 28, 2007. Mr. Maekawa served as Managing Director and General Manager of Finance & Accounting Division, Corporate Planning Division and Information Systems Division of Nippon Shinyaku Co. Ltd. He has been Representative Director of Nippon Shinyaku Co. Ltd. since June 2005.

CEO Compensation
  • Insufficient data for Shigenobu to compare compensation growth.
  • Insufficient data for Shigenobu to establish whether their remuneration is reasonable compared to companies of similar size in United States of America.
Management Team Tenure

Average tenure of the Nippon Shinyaku management team in years:

3.3
Average Tenure
  • The tenure for the Nippon Shinyaku management team is about average.
Management Team

Shigenobu Maekawa

TITLE
President & Representative Director
AGE
65
TENURE
12 yrs

Taro Sakurai

TITLE
Department Manager of Finance & Accounting Department and Corporate Officer

Takashi Takaya

TITLE
GM of Administration Division & Director
TENURE
1 yrs

Shouzou Sano

TITLE
GM of Sales & Marketing Division and Director
TENURE
4.4 yrs

Noboru Nishikawa

TITLE
Head of Sales & Marketing Planning Division and Corporate Officer
TENURE
0.4 yrs

Koji Honma

TITLE
General Manager of Personnel Dept. & Corporate Officer

Akira Matsuura

TITLE
MD, GM of Research & Development Division and Director
AGE
65
TENURE
9 yrs

Hirokata Harada

TITLE
Corporate Officer & Head of Medical Supervisory Division

Hisashi Suehara

TITLE
Head of Regulatory Affairs Supervision & Assurance Department and Corporate Officer

Hiromu Nakajima

TITLE
Chief Medical Officer & Corporate Officer
TENURE
2.2 yrs
Board of Directors Tenure

Average tenure and age of the Nippon Shinyaku board of directors in years:

4.7
Average Tenure
65
Average Age
  • The tenure for the Nippon Shinyaku board of directors is about average.
Board of Directors

Shigenobu Maekawa

TITLE
President & Representative Director
AGE
65
TENURE
14 yrs

Takashi Takaya

TITLE
GM of Administration Division & Director
TENURE
1 yrs

Shouzou Sano

TITLE
GM of Sales & Marketing Division and Director
TENURE
4.4 yrs

Akira Matsuura

TITLE
MD, GM of Research & Development Division and Director
AGE
65
TENURE
9 yrs

Hitoshi Saito

TITLE
GM of Resource Procurement
AGE
63
TENURE
5 yrs

Kenro Kobayashi

TITLE
GM of Functional Food Division & Director
TENURE
4.4 yrs

Takanori Edamitsu

TITLE
GM of Business Management & Director
TENURE
1 yrs

Hitoshi Sakata

TITLE
External Director
AGE
65
TENURE
6.4 yrs

Yukio Sugiura

TITLE
External Director
AGE
76
TENURE
6 yrs

Miyuki Sakurai

TITLE
External Director
TENURE
1.9 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
X
Management checks
We assess Nippon Shinyaku's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
    5. Nippon Shinyaku has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

NPPN.Y News

Simply Wall St News

NPPN.Y Company Info

Description

Nippon Shinyaku Co., Ltd. manufactures and sells pharmaceuticals and foodstuffs in Japan, Europe, and internationally. The company operates through Pharmaceuticals and Functional Food segments. It offers drugs for urological diseases, inflammation and allergies, hematologic malignancies, cardiovascular and metabolic diseases, gastrointestinal disorders, and other diseases. Its products comprise Zalutia for urinary disorder caused by benign prostatic; Eviprostat for prostatic hypertrophy; Bladderon for pollakisuria; Estracyt for prostate cancer; Cialis for erectile dysfunction; Vidaza for myelodysplastic syndrome; Cylocide for solid tumor and acute leukemia; CylocideN for relapsed and refractory acute leukemia and malignant lymphoma; and Trisenox and Amnolake for relapsed and refractory acute promyelocytic leukemia. The company’s products also include Uptravi, Adcirca, and Opsumit for pulmonary arterial hypertension; Regtect for maintaining alcohol abstinence; Lunabel LD and Lunabel ULD for dysmenorrhea; Erizas, a dry powder inhaler solution for allergic rhinitis; Baynas for allergic rhinitis; Azunol Gargle liquid, a gargling solution containing azulene; Cephadol for vertigo; Livostin for allergic rhinitis and conjunctivitis; and Onetram and Tramal for cancer and chronic pain. In addition, it researches and develops, and markets drugs in the areas of urology, gynecology, otorhinolaryngology, and orthopedics. In addition, the company provides functional foods, such as health food ingredients, preservatives, protein preparations, and spice and condiments. Nippon Shinyaku Co., Ltd. was founded in 1911 and is headquartered in Kyoto, Japan.

Details
Name: Nippon Shinyaku Co., Ltd.
NPPN.Y
Exchange: OTCPK
Founded: 1911
¥5,233,690,406
67,354,239
Website: http://www.nippon-shinyaku.co.jp
Address: Nippon Shinyaku Co., Ltd.
14, Nishinosho-Monguchi-cho,
Kisshoin,
Kyoto,
601-8550,
Japan
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
TSE 4516 Common Stock The Tokyo Stock Exchange JP JPY 06. Jan 1992
OTCPK NPPN.Y ADR Pink Sheets LLC US USD 10. Nov 2016
Number of employees
Current staff
Staff numbers
1,928
Nippon Shinyaku employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/06/20 01:17
End of day share price update: 2019/05/28 00:00
Last estimates confirmation: 2019/06/19
Last earnings filing: 2019/05/13
Last earnings reported: 2019/03/31
Last annual earnings reported: 2019/03/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Related Companies

© 2019 Simply Wall Street Pty Ltd, Community Design 2845206, US Design Patent #29/544/281, European Design Registration #2845206, Standard & Poor’s Financial Services LLC. All rights reserved.

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.

Copyright © 2019, Standard & Poor’s Financial Services LLC. Reproduction of S&P Capital IQ in any form is prohibited except with the prior written permission of S&P. S&P does not guarantee the accuracy, adequacy, completeness or availability of any information and is not responsible for any errors or omissions, regardless of the cause or for the results obtained from the use of such information. S&P DISCLAIMS ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE. In no event shall S&P be liable for any direct, indirect, special or consequential damages, costs, expenses, legal fees, or losses (including lost income or lost profit and opportunity costs) in connection with subscriber’s or others’ use of S&P Capital IQ. (2019)